Laurantis Pharma Oy and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin™ Investigational Treatment for Breast Cancer-Associated Lymphedema
10/15/2012 9:07:15 AM
More...
|
Ark Therapeutics Led Consortium Wins €5.3 Million EU Framework Program 7 Grant
7/14/2011 9:22:41 AM
More...
|
Ark Therapeutics Receives €0.6 Million Finnish Grants for Development of Lentiviral Production Platform
7/6/2011 1:26:15 PM
More...
|
Ark Therapeutics Interim Management Statement
5/17/2011 10:50:40 AM
More...
|
Ark Therapeutics Preliminary Results for the Year Ended 31 December 2010
3/9/2011 9:30:05 AM
More...
|
Ark Therapeutics Release: Appointment of CFO, Russell Banks
3/3/2011 11:22:38 AM
More...
|
Ark Therapeutics Board Changes, Dr David Bloxham Appointed Non-executive Director
2/22/2011 10:50:15 AM
More...
|
Ark Therapeutics Release: Disposal of the Majority of the Group's Woundcare Business for up to £2.7 Million
2/8/2011 9:11:02 AM
More...
|
Positive Results Gor Ark Therapeutics Pre-Clinical Product Candidate EG013 in the Treatment of Foetal Growth Restriction
11/29/2010 11:45:50 AM
More...
|
Ark Therapeutics Restructures, Cuts Headcount and Looks for Partners
9/9/2010 8:15:56 AM
More...
|
|